Edwards Lifesciences Interest Income decreased by 8.2% to $33.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.2%, from $36.50M to $33.50M. Over 3 years (FY 2021 to FY 2024), Interest Income shows an upward trend with a 90.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher interest income suggests a strong cash position or a favorable interest rate environment for the company's investments.
Interest income is the revenue earned from cash deposits, marketable securities, and other interest-bearing investments....
Varies based on cash management strategies; companies with large cash piles will report higher interest income than those with high debt.
interest_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.35M | $4.35M | $4.35M | $8.88M | $8.88M | $8.88M | $8.88M | $16.80M | $16.80M | $16.80M | $16.80M | $30.08M | $30.08M | $30.08M | $30.08M | $36.50M | $33.50M |
| QoQ Change | — | +0.0% | +0.0% | +104.0% | +0.0% | +0.0% | +0.0% | +89.3% | +0.0% | +0.0% | +0.0% | +79.0% | +0.0% | +0.0% | +0.0% | +21.4% | -8.2% |
| YoY Change | — | — | — | — | +104.0% | +104.0% | +104.0% | +89.3% | +89.3% | +89.3% | +89.3% | +79.0% | +79.0% | +79.0% | +79.0% | +21.4% | -8.2% |